Cellmid 2017 Annual Report

CEO

REPORT

CONTINUED

LYRAMID’S DIAGNOSTIC PATENTS CONTINUE

TO DELIVER REVENUE

Lyramid’s diagnostic patents have been licensed to three

groups; Quest, Paciﬁc Edge and Fujikura Kasei. Paciﬁc

Edge developed and commercialised its CxBladder

cancer test and we have been receiving revenue from

the sales since 2015. The other two companies have not

commercialised their diagnostic products as yet.

Paciﬁc Edge, a listed diagnostic company based in New

Zealand, licensed midkine (MK) in 2010 for the use in its

tests for the diagnosis, prognosis and disease management

of bladder cancer. The Company received a total revenue

of $1,221,0448 to date from the Paciﬁc Edge license. This

doesn’t include the royalty payment for the six months

ending 31 March 2017, which was received after the

closing of the 2017 ﬁnancial year.

Paciﬁc Edge announced the achievement of a number of

material milestones during reporting period, some of these

are listed below. They have also reported a 62% increase

in operating revenue to $8.1 million for the 2017 ﬁnancial

year (ended on 31 March 2017).

• In October 2016 Paciﬁc Edge became Approved Provider

to Tricare Health Plan Networks in the US, which provides

health care to 9.4 million beneﬁciaries of the US Military

Health system.

• In October 2016 CxBladder® Monitor was adopted

as a replacement for cystoscopy for low risk patients

monitored for recurrence of bladder cancer by the

Waitemata District Health Board.

• In December 2016 clinical study results of CxBladder®

Monitor were accepted for publication in the American

Journal of Urology. The study conﬁrmed strong

performance (93% sensitivity and 97% negative

predictive value) of the test and the potential of it to

replace cystoscopy in low risk patients.

Paciﬁc Edge, in their most recent Annual Report,

foreshadowed increase in CxBladder® sales as the utility

and application of the test continues to broaded.

KINERA LIMITED –

MK MANUFACTURE SUPPORTING

PRE-IND WORK

Kinera has a broad patent portfolio using MK protein for

the treatment of ischemic conditions including heart attack

and stroke, and covering the manufacturing process for

MK using Pichia pastoris. Extensive pre-clinical evidence

has been unequivocal in demonstrating the beneﬁt of

single or chronic MK dosing in improving mortality and

cardiac output following heart attack in animal models or

this disease.

Coronary heart disease remains the biggest cause of

mortality world-wide and, whilst mortality rates have been

improving, there is an urgent need for better management

of myocardial infarct in those surviving an acute event.

Minimising damage to heart muscle during ischemia and

from the subsequent injury following restoration of blood

ﬂow is not addressed by current medications.